Hiroshige Yoshioka-Tanaka

Hirakata, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Model-based dose selection and pharmacokinetic bridging of subcutaneous from intravenous pembrolizumab across indications.

Model-based dose selection and pharmacokinetic bridging of subcutaneous from intravenous pembrolizumab across indications.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 14, 2025

Association between skin toxicity and efficacy of necitumumab in squamous non-small-cell lung cancer: a pooled analysis of two randomized clinical trials-SQUIRE and JFCM.

Association between skin toxicity and efficacy of necitumumab in squamous non-small-cell lung cancer: a pooled analysis of two randomized clinical trials-SQUIRE and JFCM.

Journal: ESMO open

Published: June 23, 2023

Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.

Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: September 06, 2019

A Phase II Study of Cisplatin Plus Gemcitabine followed by Maintenance Gemcitabine for Advanced Squamous Non-Small-Cell Lung Cancer: Kyoto Thoracic Oncology Research Group 1302.

A Phase II Study of Cisplatin Plus Gemcitabine followed by Maintenance Gemcitabine for Advanced Squamous Non-Small-Cell Lung Cancer: Kyoto Thoracic Oncology Research Group 1302.

Journal: Oncology

Published: June 12, 2019

Phase II Study of Weekly Amrubicin for Refractory or Relapsed Small Cell Lung Cancer.

Phase II Study of Weekly Amrubicin for Refractory or Relapsed Small Cell Lung Cancer.

Journal: In vivo (Athens, Greece)

Published: August 02, 2018

A statistical issue regarding the original paper by M. Tamiya and others (Med Oncol (2016) 33:2 DOI 10.1007/s12032-015-0715-7).

A statistical issue regarding the original paper by M. Tamiya and others (Med Oncol (2016) 33:2 DOI 10.1007/s12032-015-0715-7).

Journal: Medical oncology (Northwood, London, England)

Published: March 20, 2017

Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer.

Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer.

Journal: BMC cancer

Published: January 25, 2017

Detection of epidermal growth factor receptor gene T790M mutation in cytology samples using the cobas® EGFR mutation test.

Detection of epidermal growth factor receptor gene T790M mutation in cytology samples using the cobas® EGFR mutation test.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: November 30, 2016

A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study).

A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study).

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: March 20, 2015

Efficacy and safety of erlotinib in elderly patients in the phase IV POLARSTAR surveillance study of Japanese patients with non-small-cell lung cancer.

Efficacy and safety of erlotinib in elderly patients in the phase IV POLARSTAR surveillance study of Japanese patients with non-small-cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: June 05, 2014

Showing 1-10 of 10

Last Updated: 09/26/2026